<DOC>
	<DOC>NCT01235936</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of repeat doses of orally administered AKB-6548 in pre-dialysis subjects with anemia.</brief_summary>
	<brief_title>Safety and Efficacy Study for AKB-6548 in Subjects With Chronic Kidney Disease and Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Key 18 to 79 years of age, inclusive Chronic Kidney Disease Stage 3 or Stage 4 Hemoglobin (Hgb) &lt; 10.5 g/dl TSAT &gt; 20% and CBC indicating normocytic red blood cell morphology Key BMI &gt; 40 Red blood cell transfusion within 12 weeks. Androgen therapy within the previous 21 days prior to study dosing Therapy with any approved or experimental erythropoiesis stimulating agent (ESA) within the 10 weeks prior to the Screening visit Subjects meeting the criteria of ESA resistance within the previous 4 months Individual doses of intravenous iron of 250 mg or larger within the past 21 days AST or ALT &gt;1.8x ULN. Alkaline phosphatase &gt;2x ULN. Total bilirubin &gt;1.5x ULN. Uncontrolled hypertension New York Heart Association Class III or IV congestive heart failure Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal insufficiency</keyword>
	<keyword>renal impairment</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>